This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2005 Apr 1;10(7):449-51.

doi: 10.1016/S1359-6446(05)03418-5.

Less is more: the human microdosing concept

PMID: 15809185
DOI: 10.1016/S1359-6446(05)03418-5

Editorial

Less is more: the human microdosing concept

R Colin Garner. Drug Discov Today. 2005.

. 2005 Apr 1;10(7):449-51.

doi: 10.1016/S1359-6446(05)03418-5.

Author

PMID: 15809185
DOI: 10.1016/S1359-6446(05)03418-5

No abstract available

PubMed Disclaimer

Similar articles

Improved early clinical development through human microdosing studies.
Wilding IR, Bell JA. Wilding IR, et al. Drug Discov Today. 2005 Jul 1;10(13):890-4. doi: 10.1016/S1359-6446(05)03509-9. Drug Discov Today. 2005. PMID: 15993808 Review. No abstract available.
Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.
Lappin G, Garner RC. Lappin G, et al. Nat Rev Drug Discov. 2003 Mar;2(3):233-40. doi: 10.1038/nrd1037. Nat Rev Drug Discov. 2003. PMID: 12612650 Review.
American College of Clinical Pharmacology position statement on the use of microdosing in the drug development process.
Bertino JS Jr, Greenberg HE, Reed MD; American College of Clinical Pharmacology. Bertino JS Jr, et al. J Clin Pharmacol. 2007 Apr;47(4):418-22. doi: 10.1177/0091270006299092. J Clin Pharmacol. 2007. PMID: 17389550 No abstract available.
Commentary on ACCP position statement on the use of microdosing in the drug development process.
Rowland M. Rowland M. J Clin Pharmacol. 2007 Dec;47(12):1595-6; author reply 1597-8. doi: 10.1177/0091270007310548. J Clin Pharmacol. 2007. PMID: 18048576 No abstract available.
The future of drug safety testing: expanding the view and narrowing the focus.
Stevens JL, Baker TK. Stevens JL, et al. Drug Discov Today. 2009 Feb;14(3-4):162-7. doi: 10.1016/j.drudis.2008.11.009. Epub 2009 Jan 3. Drug Discov Today. 2009. PMID: 19100337 Review.

See all similar articles

Cited by

The impact of FDA and EMEA guidelines on drug development in relation to Phase 0 trials.
Marchetti S, Schellens JH. Marchetti S, et al. Br J Cancer. 2007 Sep 3;97(5):577-81. doi: 10.1038/sj.bjc.6603925. Epub 2007 Aug 28. Br J Cancer. 2007. PMID: 17726450 Free PMC article. Review.
Microdosing and drug development: past, present and future.
Lappin G, Noveck R, Burt T. Lappin G, et al. Expert Opin Drug Metab Toxicol. 2013 Jul;9(7):817-34. doi: 10.1517/17425255.2013.786042. Epub 2013 Apr 4. Expert Opin Drug Metab Toxicol. 2013. PMID: 23550938 Free PMC article. Review.
Phase 0 - Microdosing strategy in clinical trials.
Rani PU, Naidu MU. Rani PU, et al. Indian J Pharmacol. 2008 Nov;40(6):240-2. doi: 10.4103/0253-7613.45147. Indian J Pharmacol. 2008. PMID: 21279177 Free PMC article.
Microdosing assessment to evaluate pharmacokinetics and drug metabolism in rats using liquid chromatography-tandem mass spectrometry.
Ni J, Ouyang H, Aiello M, Seto C, Borbridge L, Sakuma T, Ellis R, Welty D, Acheampong A. Ni J, et al. Pharm Res. 2008 Jul;25(7):1572-82. doi: 10.1007/s11095-008-9555-x. Epub 2008 Feb 26. Pharm Res. 2008. PMID: 18299965
Quantifying exploratory low dose compounds in humans with AMS.
Dueker SR, Vuong le T, Lohstroh PN, Giacomo JA, Vogel JS. Dueker SR, et al. Adv Drug Deliv Rev. 2011 Jun 19;63(7):518-31. doi: 10.1016/j.addr.2010.10.009. Epub 2010 Oct 31. Adv Drug Deliv Rev. 2011. PMID: 21047543 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information